Featured 13F manager
Farallon Capital Management, L.l.c.
San Francisco, CA 87 processed 13Fs on this site · 2021 Q3–2026 Q2
- $21.7B
- 77 Positions
- 2026 Q2
- +23.6% QoQ
- Top 5 29.9%
Portfolio
top 5 29.9% · top 10 44.0%
- RVMD - Revolution Medicines 11.7%
- EA - Electronic Arts 7.5%
- BBIO - Bridgebio Pharma 3.7%
- PTGX - Protagonist Therapeutics 3.6%
- EXEL - Exelixis 3.4%
- LQDA - Liquidia 3.1%
- AMZN - Amazon 2.9%
- LNTH - Lantheus 2.9%
- NTRA - Natera 2.8%
- UNH - Unitedhealth Group 2.4%
- TMO - Thermo Fisher Scientific 2.4%
- ROIV - Roivant Sciences 2.3%
- Other 51.3%
AUM over time
Book
| IQV - IQVIA | 4.38% | Add +1.6% | 3,258,112 | $204.89 | $668M | +50,530 | +$87M |
| TMO - Thermo Fisher Scientific | 4.19% | Add +3.6% | 1,161,959 | $550.69 | $640M | +39,900 | +$71M |
| TRU - Transunion | 3.30% | Add +12.1% | 8,863,895 | $56.75 | $503M | +956,000 | +$33M |
| CRM - Salesforce | 3.29% | Add +83.5% | 3,780,838 | $132.59 | $501M | +1,719,900 | +$205M |
| ARMK - Aramark | 2.93% | Reduce −32.0% | 10,828,884 | $41.34 | $448M | −5,092,758 | −$49M |
| BSX - Boston Scientific | 2.81% | Reduce −23.8% | 9,260,257 | $46.27 | $428M | −2,891,000 | −$42M |
| MSFT - Microsoft | 2.65% | Add +17.3% | 1,688,478 | $239.82 | $405M | +249,300 | +$70M |
| AZNN — | 2.61% | Add +5.2% | 5,876,462 | $67.80 | $398M | +291,500 | +$92M |
| CNC - Centene Del | 2.47% | Add +8.0% | 4,591,541 | $82.01 | $377M | +339,400 | +$46M |
| SPGI - S&P Global | 2.36% | Add +50.1% | 1,077,100 | $334.94 | $361M | +359,600 | +$142M |
| INTU - Intuit | 2.30% | New | 902,100 | $389.22 | $351M | +902,100 | +$351M |
| YMM - Full Truck Alliance | 2.28% | Reduce −3.8% | 43,439,743 | $8.00 | $348M | −1,725,000 | +$52M |
| EFX - Equifax | 2.17% | Reduce −4.6% | 1,702,497 | $194.36 | $331M | −82,600 | +$25M |
| SHW - Sherwin Williams | 2.16% | Add +8.3% | 1,385,792 | $237.33 | $329M | +106,300 | +$67M |
| ELV - Elevance Health | 2.13% | Reduce −20.9% | 634,300 | $512.97 | $325M | −167,100 | −$39M |
| HWM - Howmet Aerospace | 2.09% | Reduce −17.6% | 8,107,353 | $39.41 | $320M | −1,735,000 | +$15M |
| MA - Mastercard · CL A | 2.09% | Reduce −14.2% | 916,171 | $347.73 | $319M | −152,200 | +$15M |
| DT - Dynatrace | 1.99% | Add +9.9% | 7,918,269 | $38.30 | $303M | +716,269 | +$53M |
| WAB - Wabtec | 1.79% | Reduce −21.8% | 2,737,930 | $99.81 | $273M | −765,000 | −$12M |
| GOOG - Alphabet · CL C | 1.76% | Reduce −10.2% | 3,026,140 | $88.73 | $269M | −345,000 | −$56M |
| NOW - Servicenow | 1.70% | Add +35.5% | 668,650 | $388.27 | $260M | +175,100 | +$73M |
| V - VISA · CL A | 1.70% | Reduce −17.4% | 1,249,010 | $207.76 | $259M | −263,200 | −$9M |
| BX - Blackstone | 1.58% | Add +4.3% | 3,248,951 | $74.19 | $241M | +134,000 | −$20M |
| AON - AON PLC · CL A | 1.55% | Reduce −2.5% | 788,086 | $300.14 | $237M | −20,400 | +$20M |
| BABA - Alibaba Group | 1.54% | Add +473.5% | 2,661,000 | $88.09 | $234M | +2,197,000 | +$197M |
| XYZ - Block · CL A | 1.33% | Add +24.5% | 3,218,000 | $62.84 | $202M | +634,000 | +$60M |
| NYT - New York Times · CL A | 1.29% | Reduce −22.5% | 6,068,791 | $32.46 | $197M | −1,759,282 | −$28M |
| UTHR - United Therapeutics | 1.20% | Add +19.3% | 655,873 | $278.09 | $182M | +106,200 | +$67M |
| CSGP - Costar Group | 1.16% | Reduce −23.0% | 2,280,185 | $77.28 | $176M | −680,000 | −$30M |
| EXEL - Exelixis | 1.14% | Add +1.8% | 10,868,149 | $16.04 | $174M | +192,305 | +$7M |
| BIIB - Biogen | 1.08% | Add +94.0% | 592,699 | $276.92 | $164M | +287,200 | +$83M |
| ABBV - Abbvie | 0.99% | Add +29.5% | 939,212 | $161.61 | $152M | +214,100 | +$54M |
| HUM - Humana | 0.91% | Add +7.6% | 270,400 | $512.19 | $138M | +19,200 | +$17M |
| BEAM - Beam Therapeutics | 0.87% | Reduce −6.4% | 3,399,921 | $39.11 | $133M | −231,350 | −$40M |
| CLVT - Clarivate | 0.83% | Reduce −62.6% | 15,177,433 | $8.34 | $127M | −25,368,867 | −$254M |
| Sarepta Therapeutics | 0.79% | Add +23.0% | 928,900 | $129.58 | $120M | +173,950 | +$37M |
| Masimo | 0.74% | Add +31.5% | 758,500 | $147.95 | $112M | +181,500 | +$31M |
| PCG - Pg And E | 0.55% | Reduce −18.2% | 5,155,142 | $16.26 | $84M | −1,150,000 | +$5M |
| BEKE - KE | 0.53% | Reduce −42.2% | 5,758,500 | $13.96 | $80M | −4,200,000 | −$94M |
| CYTK - Cytokinetics | 0.51% | Add +5.0% | 1,701,738 | $45.82 | $78M | +80,700 | −$565K |
| Lufax · CL A | 0.49% | Add +87.2% | 38,436,399 | $1.94 | $75M | +17,900,000 | +$22M |
| ENTA - Enanta Pharmaceuticals | 0.47% | Hold | 1,550,000 | $46.52 | $72M | — | — |
| CVS - Cvs Health | 0.42% | Reduce −44.7% | 694,259 | $93.19 | $65M | −562,000 | −$55M |
| INSP - Inspire Med Sys | 0.40% | Reduce −49.7% | 242,596 | $251.88 | $61M | −239,400 | −$24M |
| BRKR - Bruker | 0.38% | Reduce −9.0% | 859,300 | $68.35 | $59M | −84,500 | +$9M |
| AGIO - Agios Pharmaceuticals | 0.37% | Add +35.3% | 2,025,829 | $28.08 | $57M | +529,000 | +$15M |
| MDGL - Madrigal Pharmaceuticals | 0.29% | New | 153,000 | $290.25 | $44M | +153,000 | +$44M |
| RVMD - Revolution Medicines | 0.27% | Reduce −32.1% | 1,698,015 | $23.82 | $40M | −801,985 | −$9M |
| PTGX - Protagonist Therapeutics | 0.26% | Hold | 3,651,887 | $10.91 | $40M | — | — |
| Legend Biotech | 0.24% | Add +214.1% | 746,614 | $49.92 | $37M | +508,900 | +$28M |
| JAZZ - Jazz Pharmaceuticals | 0.24% | Reduce −57.2% | 229,800 | $159.31 | $37M | −307,700 | −$35M |
| PACB — | 0.21% | New | 4,004,400 | $8.18 | $33M | +4,004,400 | +$33M |
| Iveric Bio | 0.21% | Add +11.0% | 1,462,000 | $21.41 | $31M | +145,000 | +$8M |
| ALNY - Alnylam Pharmaceuticals | 0.20% | Reduce −69.6% | 130,056 | $237.65 | $31M | −298,400 | −$55M |
| Holding · CL A | 0.18% | Hold | 2,809,000 | $9.96 | $28M | — | — |
| Berenson Acquisition I · CL A | 0.16% | Hold | 2,475,000 | $10.14 | $25M | — | — |
| Metals Acquisition · CL A | 0.16% | Hold | 2,489,700 | $10.01 | $25M | — | — |
| APLSUSD - Apellis Pharmaceuticals | 0.15% | Reduce −5.8% | 450,400 | $51.71 | $23M | −27,600 | −$9M |
| Cara Therapeutics | 0.15% | Reduce −17.0% | 2,074,200 | $10.74 | $22M | −425,800 | −$1M |
| BNTX - Biontech Se | 0.14% | New | 140,000 | $150.22 | $21M | +140,000 | +$21M |
| Swiftmerge Acquisition · CLASS A | 0.13% | Hold | 1,980,000 | $10.13 | $20M | — | — |
| Holding · CLASS A | 0.12% | Hold | 1,900,000 | $10.02 | $19M | — | — |
| Sdcl Edge Acquisition · CL A | 0.11% | Hold | 1,732,500 | $10.06 | $17M | — | — |
| Broadmark Rlty Cap | 0.11% | Hold | 4,850,000 | $3.56 | $17M | — | — |
| Vector Acquisition Ii · CL A | 0.11% | Hold | 1,700,000 | $10.10 | $17M | — | — |
| Prometheus Biosciences | 0.10% | New | 145,100 | $110.00 | $16M | +145,100 | +$16M |
| Savara | 0.10% | Add +2.3% | 10,134,961 | $1.55 | $16M | +226,875 | +$351K |
| Ares Acquisition · CL A | 0.09% | Hold | 1,425,000 | $10.07 | $14M | — | — |
| Disruptive Acquisition · CLASS A | 0.09% | Hold | 1,400,000 | $10.08 | $14M | — | — |
| BHVN - Biohaven | 0.09% | Add +325.5% | 1,000,000 | $13.88 | $14M | +765,000 | +$12M |
| Holding · CLASS A | 0.09% | Hold | 1,360,040 | $10.05 | $14M | — | — |
| Reata Pharmaceuticals · CL A | 0.08% | New | 332,000 | $37.99 | $13M | +332,000 | +$13M |
| Forest Road Acquisition Cor · CL A | 0.08% | Hold | 1,250,000 | $10.04 | $13M | — | — |
| Tcv Acquisition · CL A | 0.08% | Hold | 1,211,459 | $10.10 | $12M | — | — |
| Agile Growth · CLASS A | 0.08% | Hold | 1,200,000 | $10.09 | $12M | — | — |
| Zymeworks Del | 0.08% | New | 1,500,000 | $7.86 | $12M | +1,500,000 | +$12M |
| Holding · CL A | 0.07% | Hold | 1,120,102 | $10.10 | $11M | — | — |
| FHN - First Horizon | 0.07% | New | 455,000 | $24.50 | $11M | +455,000 | +$11M |
| AVTR - Avantor | 0.07% | Reduce −85.6% | 528,464 | $21.09 | $11M | −3,151,000 | −$61M |
| Tpg Pace Beneficial Ii | 0.07% | Hold | 1,116,833 | $9.82 | $11M | — | — |
| Holding · CLASS A | 0.07% | Hold | 1,000,000 | $10.10 | $10M | — | — |
| VNET - VNET Group | 0.07% | Add +115.2% | 1,775,000 | $5.67 | $10M | +950,000 | +$6M |
| Forum Merger Iv · CLASS A | 0.07% | Hold | 1,000,000 | $10.05 | $10M | — | — |
| Churchill Capital Vi · CL A | 0.07% | Hold | 997,767 | $9.99 | $10M | — | — |
| Churchill Capital Vii · CL A | 0.07% | Hold | 1,000,000 | $9.97 | $10M | — | — |
| Screaming Eagle Acquisitn · CLASS A | 0.07% | Hold | 1,000,000 | $9.94 | $10M | — | — |
| Atento S A | 0.06% | Hold | 2,230,357 | $4.23 | $9M | — | — |
| Holding · CL A | 0.06% | Hold | 900,000 | $10.27 | $9M | — | — |
| GPOR - Gulfport Energy | 0.06% | Reduce −0.3% | 116,020 | $73.64 | $9M | −388 | −$2M |
| EVH - Evolent Health · CL A | 0.06% | New | 302,000 | $28.08 | $8M | +302,000 | +$8M |
| Holding · CLASS A | 0.06% | Hold | 835,638 | $10.08 | $8M | — | — |
| Holding | 0.06% | Hold | 848,184 | $9.93 | $8M | — | — |
| Holding · CL A | 0.05% | Hold | 800,000 | $10.10 | $8M | — | — |
| Arya Sciences Acqu Iv · CL A | 0.05% | Hold | 800,000 | $10.10 | $8M | — | — |
| Levere · CLASS A | 0.05% | Hold | 800,000 | $10.09 | $8M | — | — |
| Holding · CL A | 0.05% | Hold | 775,200 | $10.20 | $8M | — | — |
| Holding · CLASS A | 0.05% | Hold | 750,000 | $10.25 | $8M | — | — |
| Panacea Acquisition Ii · CL A | 0.05% | Hold | 750,000 | $10.09 | $8M | — | — |
| Holding · CL A | 0.05% | Hold | 750,000 | $10.09 | $8M | — | — |
| Pathfinder Acquisition · CL A | 0.05% | Hold | 750,000 | $10.08 | $8M | — | — |
| Holding · CL A | 0.05% | Hold | 750,000 | $10.02 | $8M | — | — |
| Holding · CLASS A | 0.05% | Hold | 745,000 | $10.06 | $7M | — | — |
| Holding · CL A | 0.05% | Hold | 700,000 | $10.08 | $7M | — | — |
| Corsair Partnering · CL A | 0.05% | Hold | 700,000 | $10.02 | $7M | — | — |
| Khosla Ventures Acquisition · CL A | 0.05% | Hold | 700,000 | $9.98 | $7M | — | — |
| Rocket Internet Grwt Oprt · CL A | 0.04% | Hold | 647,945 | $10.10 | $7M | — | — |
| Rcf Acquisition · CL A | 0.04% | Hold | 600,000 | $10.26 | $6M | — | — |
| Holding · CLASS A | 0.04% | Hold | 600,000 | $10.25 | $6M | — | — |
| Finserv Acquisition Ii · CL A | 0.04% | Hold | 600,000 | $10.05 | $6M | — | — |
| SLAM · CL A | 0.04% | Hold | 570,396 | $10.10 | $6M | — | — |
| NTRA - Natera | 0.04% | Reduce −37.2% | 143,200 | $40.17 | $6M | −84,753 | −$4M |
| Blue Whale Acquisition · CLASS A | 0.04% | Hold | 575,000 | $9.79 | $6M | — | — |
| Tio Tech A · CLASS A | 0.03% | Hold | 502,001 | $10.10 | $5M | — | — |
| Ftac Hera Acquisition · CLASS A | 0.03% | Hold | 500,000 | $10.12 | $5M | — | — |
| G Squared Ascend I · CL A | 0.03% | Hold | 500,000 | $10.10 | $5M | — | — |
| Holding · CL A | 0.03% | Hold | 500,000 | $10.07 | $5M | — | — |
| ALVO - Alvotech | 0.03% | Hold | 500,000 | $10.00 | $5M | — | — |
| Gores Ix · CLASS A | 0.03% | Hold | 500,000 | $9.92 | $5M | — | — |
| Generation Bio | 0.03% | Reduce −50.0% | 1,249,382 | $3.93 | $5M | −1,250,618 | −$8M |
| Holding · CL A | 0.03% | Hold | 484,709 | $9.85 | $5M | — | — |
| Scion Tech Growth Ii · CL A | 0.03% | Hold | 450,000 | $10.12 | $5M | — | — |
| Ldh Growth I · CLASS A | 0.03% | Hold | 436,702 | $10.07 | $4M | — | — |
| Svf Investment · CL A | 0.03% | Hold | 425,000 | $10.11 | $4M | — | — |
| Vpc Impact Acquisition · CLASS A | 0.03% | Hold | 425,000 | $10.11 | $4M | — | — |
| Blueprint Medicines | 0.03% | New | 94,000 | $43.81 | $4M | +94,000 | +$4M |
| Lamf Global Ventures I · CLASS A | 0.03% | Hold | 400,000 | $10.25 | $4M | — | — |
| Holding · CL A | 0.03% | Hold | 400,000 | $10.16 | $4M | — | — |
| NUVB - Nuvation Bio · CL A | 0.03% | Reduce −27.0% | 2,117,600 | $1.92 | $4M | −782,400 | −$2M |
| Holding · CLASS A | 0.03% | Hold | 400,000 | $10.05 | $4M | — | — |
| Cartica Acquisition · CLASS A | 0.02% | Hold | 350,000 | $10.35 | $4M | — | — |
| Holding · CLASS A | 0.02% | Hold | 350,000 | $10.20 | $4M | — | — |
| Uta Acquisition · CLASS A | 0.02% | Hold | 344,100 | $10.21 | $4M | — | — |
| Sound Point Acquisition · CLASS A | 0.02% | Hold | 300,000 | $10.87 | $3M | — | — |
| Holding · CLASS A | 0.02% | Hold | 300,000 | $10.29 | $3M | — | — |
| Lazard Growth Acquisition · CL A | 0.02% | Hold | 300,000 | $10.11 | $3M | — | — |
| Holding | 0.02% | Hold | 810,500 | $3.26 | $3M | — | — |
| Live Oak Mobility Acquisi · CL A | 0.02% | Hold | 250,000 | $10.06 | $3M | — | — |
| Arctos Northstar Acquis · CL A | 0.01% | Hold | 200,000 | $10.09 | $2M | — | — |
| TNGX - Tango Therapeutics | 0.01% | Reduce −10.0% | 270,000 | $7.25 | $2M | −30,000 | +$872K |
| Amyris | 0.01% | Reduce −83.7% | 1,000,000 | $1.53 | $2M | −5,126,642 | −$16M |
| Priveterra Acquisition · CL A | 0.01% | Hold | 150,000 | $10.06 | $2M | — | — |
| Marblegate Acquisition · CL A | 0.01% | Reduce −94.9% | 150,000 | $10.02 | $2M | −2,820,000 | −$28M |
| NTRS - Northern Trust · CL A | 0.01% | Hold | 100,000 | $10.05 | $1M | — | — |
| NTRS - Northern Trust · CL A | 0.01% | Hold | 100,000 | $10.05 | $1M | — | — |
| COGT - Cogent Biosciences | 0.01% | Reduce −65.3% | 85,139 | $11.56 | $984K | −160,000 | −$3M |
| OKLO - Altc Acquisition · CL A | 0.01% | Hold | 98,300 | $9.92 | $975K | — | — |
| Better Therapeutics | 0.01% | Reduce −18.6% | 813,556 | $1.12 | $911K | −186,444 | −$849K |
| Clever Leaves | 0.01% | Add +8.2% | 2,668,551 | $0.3070 | $819K | +201,659 | −$666K |
| Summit Midstream Partners | 0.00% | Hold | 43,055 | $16.68 | $718K | — | — |
| Avrobio | 0.00% | Hold | 740,000 | $0.7129 | $528K | — | — |
| EDU — | 0.00% | Hold | 13,000 | $34.82 | $453K | — | — |
| Karuna Therapeutics | 0.00% | Reduce −97.3% | 2,200 | $196.50 | $432K | −77,800 | −$18M |
| Holding | 0.00% | Hold | 85,838 | $2.67 | $229K | — | — |
Showing top 50 of 153 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Change Healthcare | 2.95% | Exit | 0 | $27.49 | $497M | −18,076,272 | −$497M |
| 2.02% | Exit | 0 | $43.84 | $340M | −7,755,000 | −$340M | |
| BHVN - Biohaven | 1.75% | Exit | 0 | $151.17 | $294M | −1,947,820 | −$294M |
| META - Meta Platforms · CL A | 1.46% | Exit | 0 | $135.68 | $245M | −1,807,040 | −$245M |
| ADBE - Adobe Systems | 1.14% | Exit | 0 | $275.20 | $191M | −694,772 | −$191M |
| Horizon Therapeutics Pub L | 0.65% | Exit | 0 | $61.89 | $110M | −1,780,223 | −$110M |
| Nielsen | 0.41% | Exit | 0 | $27.72 | $68M | −2,470,976 | −$68M |
| Laboratory Amer | 0.26% | Exit | 0 | $204.81 | $44M | −215,314 | −$44M |
| Chemocentryx | 0.25% | Exit | 0 | $51.66 | $41M | −800,000 | −$41M |
| Imago Biosciences | 0.22% | Exit | 0 | $15.05 | $37M | −2,471,313 | −$37M |
| Catalent | 0.20% | Exit | 0 | $72.36 | $34M | −465,755 | −$34M |
| Ironsource · CL A | 0.19% | Exit | 0 | $3.44 | $31M | −9,130,000 | −$31M |
| Holding | 0.18% | Exit | 0 | $68.10 | $31M | −450,000 | −$31M |
| Holding · CL A | 0.15% | Exit | 0 | $9.81 | $25M | −2,500,000 | −$25M |
| Revolution Healthcar Aq · CLASS A | 0.12% | Exit | 0 | $9.83 | $20M | −2,000,000 | −$20M |
| Holding · CLASS A | 0.10% | Exit | 0 | $9.97 | $17M | −1,732,500 | −$17M |
| Holding · CL A | 0.10% | Exit | 0 | $9.84 | $17M | −1,750,000 | −$17M |
| Shelter Acquisition I · CLASS A | 0.10% | Exit | 0 | $9.91 | $16M | −1,650,000 | −$16M |
| Big Sky Growth Partners · CLASS A | 0.09% | Exit | 0 | $9.78 | $15M | −1,550,000 | −$15M |
| KKR - Kkr Acquisition I · CLASS A | 0.09% | Exit | 0 | $9.84 | $15M | −1,500,000 | −$15M |
| Holding · CL A | 0.09% | Exit | 0 | $9.81 | $15M | −1,500,000 | −$15M |
| Humanco Acquisition · CL A | 0.08% | Exit | 0 | $9.96 | $14M | −1,407,749 | −$14M |
| Holding · CL A | 0.08% | Exit | 0 | $26.75 | $13M | −486,902 | −$13M |
| Holding · CL A | 0.07% | Exit | 0 | $9.85 | $12M | −1,208,326 | −$12M |
| Nightdragon Acquisition · CLASS A | 0.07% | Exit | 0 | $9.82 | $12M | −1,200,000 | −$12M |
| Gores Vii · CL A | 0.07% | Exit | 0 | $9.86 | $11M | −1,150,162 | −$11M |
| Tiga Acquisition · CL A | 0.07% | Exit | 0 | $10.38 | $11M | −1,080,000 | −$11M |
| Concord Acquisition · CL A | 0.06% | Exit | 0 | $10.05 | $10M | −1,005,100 | −$10M |
| CRBU - Caribou Biosciences | 0.06% | Exit | 0 | $10.55 | $9M | −896,369 | −$9M |
| Interprivate Ii Acquisition · CL A | 0.05% | Exit | 0 | $9.84 | $9M | −882,647 | −$9M |
| Rxr Acquisition · CLASS A | 0.05% | Exit | 0 | $9.84 | $8M | −854,961 | −$8M |
| Holding · CLASS A | 0.05% | Exit | 0 | $9.82 | $8M | −843,046 | −$8M |
| Landcadia Iv · CLASS A | 0.05% | Exit | 0 | $9.83 | $8M | −802,028 | −$8M |
| Social Leverage Acquisn · CL A | 0.04% | Exit | 0 | $9.83 | $7M | −750,000 | −$7M |
| Research Alliance Ii · CL A | 0.04% | Exit | 0 | $9.82 | $7M | −750,000 | −$7M |
| Gores Viii · CL A | 0.04% | Exit | 0 | $9.87 | $7M | −692,810 | −$7M |
| Ready Capital | 0.03% | Exit | 0 | $10.14 | $5M | −472,537 | −$5M |
| Holding · CLASS A | 0.03% | Exit | 0 | $9.83 | $4M | −452,519 | −$4M |
| Exscientia | 0.02% | Exit | 0 | $8.21 | $3M | −400,000 | −$3M |
| Holding · CL A | 0.02% | Exit | 0 | $9.82 | $3M | −304,698 | −$3M |
| Broadscale Acquisition · CL A | 0.01% | Exit | 0 | $9.85 | $2M | −250,000 | −$2M |
| Hudson Executive Inves Iii · CL A | 0.01% | Exit | 0 | $9.84 | $2M | −250,000 | −$2M |
| Ventyx Biosciences | 0.01% | Exit | 0 | $34.91 | $2M | −70,000 | −$2M |
| Liberty Media Acquisition | 0.01% | Exit | 0 | $9.94 | $2M | −210,000 | −$2M |
| Theseus Pharmaceuticals | 0.01% | Exit | 0 | $5.80 | $1M | −223,149 | −$1M |
| The Music Acquisition · CLASS A | 0.01% | Exit | 0 | $9.86 | $1M | −125,000 | −$1M |
| Crypto 1 Acquisition · CLASS A | 0.01% | Exit | 0 | $10.04 | $1M | −100,000 | −$1M |
| Ion Acquisition 3 · CL A | — | Exit | 0 | $9.87 | $554K | −56,151 | −$554K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 89 | $21.7B | +23.6% | 13F-HR | 8/14/2026 | 000090883426000432 |
| 2026 Q1 | 1 | $1.5B | — | new holds | 8/14/2026 | 000090883426000434 |
| 2026 Q1 | 172 | $17.5B | −17.2% | 13F-HR | 5/15/2026 | 000090883426000240 |
| 2025 Q4 | 1 | $1B | — | new holds | 8/14/2026 | 000090883426000433 |
| 2025 Q4 | 2 | $884M | — | new holds | 5/15/2026 | 000090883426000241 |
| 2025 Q4 | 151 | $21.2B | −13.2% | 13F-HR | 2/17/2026 | 000090883426000087 |
| 2025 Q3 | 144 | $24.4B | — | RESTATEMENT | 2/17/2026 | 000090883426000086 |
| 2025 Q3 | 144 | $24.4B | +5.4% | 13F-HR | 11/14/2025 | 000090883425000353 |
| 2025 Q2 | 1 | $140M | — | new holds | 2/17/2026 | 000090883426000085 |
| 2025 Q2 | 3 | $483M | — | new holds | 11/14/2025 | 000090883425000352 |
| 2025 Q2 | 141 | $23.2B | +29.2% | 13F-HR | 8/14/2025 | 000090883425000248 |
| 2025 Q1 | 1 | $274M | — | new holds | 2/17/2026 | 000090883426000084 |
| 2025 Q1 | 3 | $416M | — | new holds | 11/14/2025 | 000090883425000351 |
| 2025 Q1 | 7 | $2.2B | — | new holds | 8/14/2025 | 000090883425000247 |
| 2025 Q1 | 135 | $17.9B | −9.0% | 13F-HR | 5/15/2025 | 000090883425000177 |
| 2024 Q4 | 1 | $85M | — | new holds | 2/17/2026 | 000090883426000083 |
| 2024 Q4 | 2 | $349M | — | new holds | 11/14/2025 | 000090883425000350 |
| 2024 Q4 | 6 | $2.3B | — | new holds | 8/14/2025 | 000090883425000246 |
| 2024 Q4 | 4 | $333M | — | new holds | 5/15/2025 | 000090883425000180 |
| 2024 Q4 | 138 | $19.7B | −3.5% | 13F-HR | 2/14/2025 | 000090883425000081 |
| 2024 Q3 | 1 | $145M | — | new holds | 11/14/2025 | 000090883425000349 |
| 2024 Q3 | 6 | $1.5B | — | new holds | 8/14/2025 | 000090883425000243 |
| 2024 Q3 | 3 | $216M | — | new holds | 5/15/2025 | 000090883425000179 |
| 2024 Q3 | 2 | $544M | — | new holds | 2/14/2025 | 000090883425000080 |
| 2024 Q3 | 153 | $20.4B | −3.6% | 13F-HR | 11/14/2024 | 000090883424000307 |
| 2024 Q2 | 1 | $120M | — | new holds | 11/14/2025 | 000090883425000348 |
| 2024 Q2 | 5 | $1.2B | — | new holds | 8/14/2025 | 000090883425000245 |
| 2024 Q2 | 1 | $199M | — | new holds | 5/15/2025 | 000090883425000178 |
| 2024 Q2 | 2 | $452M | — | new holds | 2/14/2025 | 000090883425000079 |
| 2024 Q2 | 1 | $149M | — | new holds | 11/14/2024 | 000090883424000324 |
| 2024 Q2 | 157 | $21.2B | −4.2% | 13F-HR | 8/14/2024 | 000090883424000200 |
| 2024 Q1 | 1 | $93M | — | new holds | 11/14/2025 | 000090883425000347 |
| 2024 Q1 | 4 | $1.2B | — | new holds | 8/14/2025 | 000090883425000244 |
| 2024 Q1 | 2 | $159M | — | new holds | 2/14/2025 | 000090883425000078 |
| 2024 Q1 | 1 | $45M | — | new holds | 8/14/2024 | 000090883424000202 |
| 2024 Q1 | 167 | $22.1B | — | RESTATEMENT | 5/24/2024 | 000090883424000159 |
| 2024 Q1 | 167 | $22.1B | +9.8% | 13F-HR | 5/15/2024 | 000090883424000135 |
| 2023 Q4 | 1 | $65M | — | new holds | 11/14/2025 | 000090883425000346 |
| 2023 Q4 | 2 | $548M | — | new holds | 8/14/2025 | 000090883425000250 |
| 2023 Q4 | 5 | $1.1B | — | new holds | 5/15/2024 | 000090883424000141 |
| 2023 Q4 | 150 | $20.1B | +1.0% | 13F-HR | 2/14/2024 | 000090883424000070 |
| 2023 Q3 | 1 | $40M | — | new holds | 11/14/2025 | 000090883425000345 |
| 2023 Q3 | 1 | $40M | — | new holds | 5/15/2024 | 000090883424000138 |
| 2023 Q3 | 2 | $1.4B | — | new holds | 2/14/2024 | 000090883424000077 |
| 2023 Q3 | 1 | $1.9B | — | new holds | 2/12/2024 | 000090883424000049 |
| 2023 Q3 | 159 | $20B | +11.5% | 13F-HR | 11/14/2023 | 000090883423000150 |
| 2023 Q2 | 2 | $669M | — | new holds | 2/14/2024 | 000090883424000076 |
| 2023 Q2 | 5 | $1.4B | — | new holds | 11/14/2023 | 000090883423000157 |
| 2023 Q2 | 1 | $1.2B | — | new holds | 10/26/2023 | 000090883423000134 |
| 2023 Q2 | 165 | $17.9B | +1.3% | 13F-HR | 8/14/2023 | 000090883423000109 |
| 2023 Q1 | 2 | $234M | — | new holds | 2/14/2024 | 000090883424000075 |
| 2023 Q1 | 3 | $389M | — | new holds | 11/14/2023 | 000090883423000156 |
| 2023 Q1 | 1 | $15M | — | new holds | 8/14/2023 | 000090883423000110 |
| 2023 Q1 | 187 | $17.7B | +15.8% | 13F-HR | 5/15/2023 | 000117570723000127 |
| 2022 Q4 | 1 | $171M | — | new holds | 2/14/2024 | 000090883424000074 |
| 2022 Q4 | 3 | $485M | — | new holds | 11/14/2023 | 000090883423000155 |
| 2022 Q4 | 7 | $1B | — | new holds | 5/15/2023 | 000117570723000136 |
| 2022 Q4 | 232 | $15.3B | −9.3% | 13F-HR | 2/14/2023 | 000117570723000051 |
| 2022 Q3 | 1 | $125M | — | new holds | 2/14/2024 | 000090883424000073 |
| 2022 Q3 | 3 | $415M | — | new holds | 11/14/2023 | 000090883423000154 |
| 2022 Q3 | 5 | $411M | — | new holds | 5/15/2023 | 000117570723000135 |
| 2022 Q3 | 4 | $434M | — | new holds | 2/14/2023 | 000090966123000005 |
| 2022 Q3 | 298 | $16.8B | +3.5% | 13F-HR | 11/14/2022 | 000156761922019851 |
| 2022 Q2 | 1 | $115M | — | new holds | 2/14/2024 | 000090883424000081 |
| 2022 Q2 | 3 | $411M | — | new holds | 11/14/2023 | 000090883423000153 |
| 2022 Q2 | 2 | $337M | — | new holds | 5/15/2023 | 000117570723000134 |
| 2022 Q2 | 3 | $136M | — | new holds | 2/14/2023 | 000090966123000003 |
| 2022 Q2 | 9 | $1.2B | — | new holds | 11/14/2022 | 000156761922019862 |
| 2022 Q2 | 297 | $16.3B | −13.7% | 13F-HR | 8/15/2022 | 000156761922015953 |
| 2022 Q1 | 1 | $268M | — | new holds | 11/14/2023 | 000090883423000152 |
| 2022 Q1 | 1 | $314M | — | new holds | 5/15/2023 | 000117570723000133 |
| 2022 Q1 | 1 | $27M | — | new holds | 2/14/2023 | 000090966123000002 |
| 2022 Q1 | 3 | $186M | — | new holds | 11/14/2022 | 000156761922019864 |
| 2022 Q1 | 8 | $1.1B | — | new holds | 8/15/2022 | 000156761922015972 |
| 2022 Q1 | 307 | $18.8B | +0.4% | 13F-HR | 5/16/2022 | 000156761922010736 |
| 2021 Q4 | 1 | $227M | — | new holds | 5/15/2023 | 000117570723000132 |
| 2021 Q4 | 1 | $7M | — | new holds | 11/14/2022 | 000156761922019852 |
| 2021 Q4 | 1 | $115M | — | new holds | 8/15/2022 | 000156761922015968 |
| 2021 Q4 | 2 | $98M | — | new holds | 5/19/2022 | 000156761922011257 |
| 2021 Q4 | 6 | $833M | — | new holds | 5/16/2022 | 000156761922010757 |
| 2021 Q4 | 289 | $18.7B | −5.1% | 13F-HR | 2/14/2022 | 000156761922003965 |
| 2021 Q3 | 1 | $182M | — | new holds | 5/15/2023 | 000117570723000131 |
| 2021 Q3 | 1 | $105M | — | new holds | 8/15/2022 | 000156761922015964 |
| 2021 Q3 | 1 | $57M | — | new holds | 5/19/2022 | 000156761922011256 |
| 2021 Q3 | 3 | $998M | — | new holds | 5/16/2022 | 000156761922010753 |
| 2021 Q3 | 2 | $344M | — | new holds | 2/14/2022 | 000156761922003981 |
| 2021 Q3 | 293 | $19.7B | — | 13F-HR | 11/15/2021 | 000095012321015168 |
About
FARALLON CAPITAL MANAGEMENT, L.L.C.
87 processed 13Fs on this site · 2021 Q3–2026 Q2